PSA represents a very reliable marker in the evaluation of prostatic cancer patients. Particularly in those who have undergone radicai prostatectomy, finding dosable values of serum PSA, that theoretically shouldn't occur, must be regarded as the persistence, at least, of residuai prostatic tissue. An increase of such concentrations raises doubts of locai recurrence or metastatic disease. Every effort must be made to demonstrate this event as soon as possible in order to apply an adjuvant treatment. Non-disappearance of serum PSA at 3 months after surgery has to be inevitably considered as a lack of surgical radicality.
AnscherM.S., ProsnitzL.R.: Radiotherapy vs. hormonal therapy for the management of locally recurrent prostate cancer following radicai prostatectomy. Int. J.- Radiat. Onc. Biol. Phys., 17: 953–958, 1989.
2.
MyersR.P., FlemingT.R.: Course of localized adenocarcinoma of the prostate treated by radicai prostatectomy. Prostate, 4: 461–472, 1983.
3.
NativO., WinklerH.Z., RazY., TherneauT.M., FarrowG.M., MyersR.P., ZinckeH., LieberM.M.: Stage C prostatic adenocarcinoma: flow cytometric nuclear DNA ploidy analysis. Mayo Clin. Proc., 64: 911–919, 1989.
4.
ShevlinB.E., MittalB.B., BrandW.N., ShettyR.M.: The role of adjuvant irradiation following primary prostatectomy, based on histopathologic extent of tumour. Int. Radiat. Oncol. Biol. Phys., 16: 1425–1430, 1989.
5.
LangeP.H., ErcoleC.J., LightnerD.J., FraleyE.E., VessellaR.: The value of serum prostate specific antigen determination before and after radicai prostatectomy. J. Urol., 141: 873–879, 1989.
6.
LangeP.H.: Prostate-specific antigen for staging prior to surgery and for early detection of recurrence after surgery. Urol. Clin. North Ara., 17 (4): 813–817, 1990.
7.
KassabianV.S., BottlesK., WeaverR., WilliamsR.D., PaulsonD.F., ScardinoP.: Possible mechanism for seeding of tumour during radicai prostatectomy. J. Urol., 150: 1169–1171, 1993.
8.
TakayamaT.K., VessellaR., BrawerM.K., TrueL.D., NoteboomJ., LangeP.H.: Urinary prostate specific antigen levels after radicai prostatectomy. J. Urol., 151: 82–87, 1994.
9.
GolzR., SchubertG.E.: PSA: immunoreactivity in urachal remnants. J. Urol., 141: 1480–1482, 1989.
10.
KamoshidaS., TsutsumiY.: Extraprostatic localization of prostatic acid phosphatase and PSA: distribution in cloacogenic glandular epithelium and sex-dependent expression in human anal gland. Hum. Path., 21: 1108–1111, 1990.
11.
HudsonM.A., BahnsonR.B., CatalonaW.J.: Clinical use of prostate specific antigen with prostate cancer. J. Urol., 142: 1011–1017, 1989.
12.
OesterlingJ.E., ChanD.W., EpsteinJ.I., KimballA.W.Jr., BruzzisD.J., RockR.C., BrendlerC.B., WalshP.C.: Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radicai prostatectomy. J. Urol., 139: 766–772, 1988.
13.
StameyT.A., KabalinJ.N., McNealJ.E., JohnstoneI.N., PreihaF., RedwineE.A., YangN.: PSA in the diagnosis and treatment of adenocarcinoma of the prostate II. J. Urol., 141: 1976–1083, 1989.
14.
StameyT.A., YangN., HayA.R., McNealJ.E., FreihaF.S., RedwineE.: Prostate specific antigen as a serum marker for adenocarcinoma of the prostate. New Engl. J. Med., 317: 909–916, 1987.
15.
PontesJ.E., JabalameliP., MontieJ., FoemmelR., HowardP.D., BoyettJ.: Prognostic implications of disappearance rate of biologic markers following radicai prostatectomy. Urology, 36: 415–419, 1990.
16.
SemjonowA., HammM., RatherP.: Half life of prostate specific antigen after radicai prostatectomy: the decisive predictor of curative treatment?Eur. Urol., 21: 200–205, 1992.
17.
Van den OudenD., DavidsonP.J.T., HopW., SchoerderF.H.: Radicai prostatectomy as a monotherapy for locally advanced (stage T3) prostate cancer. J. Urol., 151: 646–651, 1994.
